22 results about "Leptin receptor" patented technology

Provided is a method for promoting sexual maturity in fish, comprising a step for inhibiting functional expression of at least one of a leptin receptor and leptin in fish. The present invention addresses the problem of providing a method for promoting sexual maturity of a fish in order to obtain an individual fish capable of ovulating or spermising at an age of 1 more than under natural or conventional culture conditions.

Provided herein are therapeutic methods of treatment using agonist leptin receptor (LEPR) antibodies, antigen-binding fragments thereof, or compositions comprising the LEPR antibodies or antigen-binding fragments thereof. Such therapeutic methods include treatment for conditions related to metabolic dysfunction, including for example, lipodystrophy, adiposity or obesity, reducing body weight, non-alcoholic fatty liver disease, hyperphagia, hyperglycemia, insulin resistance, dyslipidemia, hepatic steatosis, and infertility.

Provided herein are therapeutic methods of treatment using agonist leptin receptor (LEPR) antibodies, antigen-binding fragments thereof, or compositions comprising the LEPR antibodies or antigen-binding fragments thereof. Such therapeutic methods include treatment for conditions related to metabolic dysfunction, including for example, lipodystrophy, adiposity or obesity, reducing body weight, non-alcoholic fatty liver disease, hyperphagia, hyperglycemia, insulin resistance, dyslipidemia, hepatic steatosis, and infertility.

Leptin receptor (LEPR) is a single-pass transmembrane receptor that belongs to the cytokine receptor family. The secreted ligand Leptin binds to LEPR and activates intracellular downstream signal cascades. Leptin and LEPR play critical role in body weight regulation. The antibodies of the present disclosure have agonistic activities on LEPR and can therefore be used as therapeutic agents to treat obesity.

The invention concerns methods for treating mood disorders such as depressive disorder or episodes, or other mood disorders with current depressive episodes, by administration of a leptin receptor agonist, such as metreleptin. The invention further shows amelioration of depressive disorder or episode and related conditions in patients suffering from depression as a primary disorder, or a depressive disorder or episode as a secondary disorder and / or comorbidity. The invention also concerns methods for treating a depressive episode, or a depressive disorder.

The application discloses a rice anti-Rhizoctonia solani leptin receptor OsPLS3 protein and an encoding protein and application thereof. The rice leptin receptor OsPLS3 protein has an amino acid sequence as shown in SEQ ID NO. 3. A coding gene of the rice leptin receptor gene OsPLS3 has a genomic nucleotide sequence as shown in SEQ ID NO. 1, and an open reading frame nucleotide sequence of the rice leptin receptor gene OsPLS3 is as shown in SEQ ID NO. 2. Experiments prove that overexpression of the rice leptin receptor gene OsPLS3 in the application in rice can improve the resistance of the rice to the Rhizoctonia solani, and the rice is more susceptible to the Rhizoctonia solani after knockout, namely, the OsPLS3 positively regulates the resistance of the rice to the Rhizoctonia solani. The rice leptin receptor gene OsPLS3 has important production value for breeding of the rice resistant to the Rhizoctonia solani.

The invention provides an engineered exosome for promoting leptin sensitivity by targeting a central nervous system as well as a preparation method and application of the engineered exosome, and particularly provides RNAi for inhibiting fat synthesis, the engineered exosome for promoting leptin sensitivity by targeting the central nervous system, a preparation method of the engineered exosome and application of the engineered exosome in preparation of medicines for treating obesity. The engineered exosome prepared by the invention has SIRP alpha and MCAM proteins and can efficiently target a central nervous system, and meanwhile, the surface of the exosome is provided with a targeting peptide targeting leptin receptor neurons and LEP (61-90)-Lam2b fusion protein of leptin fragments, so that the exosome is finally combined with the leptin receptor neurons after efficiently targeting the central nervous system; the miRNAs which are loaded on the exosome and have the leptin sensitization effect can obviously improve the sensitivity of central leptin and play a role in reducing weight.

The invention belongs to the technical field of construction of experimental animal models, and particularly relates to a construction method and application of a recombinant inbred line type 2 diabetes mellitus rat model, in parent rats, female rats are SD (fa + / +) or Wistart (fa + / +), male rats are Zucker (fa + / -), heterozygote (fa + / -) female rats in filial generations obtained through hybridization are backcrossed with male parents until an F6 generation, and the female rats and the male rats are subjected to cross breeding to obtain the recombinant inbred line type 2 diabetes mellitus rat model. And hybridizing the F6 generation heterozygote (fa < + / ->) female rat with the F6 generation heterozygote (fa < + / ->) male rat to obtain a homozygote (fa <- / ->) SD / Zucker or Wistart / Zucker rat which is the recombinant inbred line type 2 diabetes mellitus rat. The obtained rats cannot express functional leptin receptors, have hyperappetite and autonomous polydipsia and polyphagia, and are very in line with real occurrence scenes of type 2 diabetes mellitus caused by overnutrition of diet under normal diet conditions of human beings.

Provided herein are compositions and methods for the treatment of Multiple Symmetric Lipomatosis (MSL) and related diseases and conditions. In particular, the present disclosure provides methods for the use of leptin receptor agonists (e.g., synthetic (e.g., recombinant) leptin, e.g., Metreleptin), in the treatment of Multiple Symmetric Lipomatosis (MSL) and related diseases and conditions.

The present invention provides a method for promoting sexual maturation of fish, the method including a step of suppressing functional expression of at least one of a leptin receptor and a leptin of the fish. An object of the present invention is to provide the method for promoting the sexual maturation of the fish in order to obtain individuals of fish capable of ovulation or spermiation at one year of age at a higher rate than in nature or under normal aquaculture conditions.

The invention concerns methods for treating unwanted body weight loss, and / or medically undesired body weight loss, or eating disorders (such as anorexia nervosa), by administration of a leptin receptor agonist, such as metreleptin. The invention also relates to methods for increasing body weight in a subject in need of the treatment.

Leptin receptor (LEPR) is a single-pass transmembrane receptor that belongs to the cytokine receptor family. The secreted ligand Leptin binds to LEPR and activates intracellular downstream signal cascades. Leptin and LEPR play critical role in body weight regulation. The antibodies of the present disclosure have agonistic activities on LEPR and can therefore be used as therapeutic agents to treat obesity.

The invention belongs to the technical field of targeted hair papilla cell lipidosome, and particularly relates to leptin modified targeted hair papilla cell lipidosome which is prepared by preparing cerium oxide nanoparticles by adopting a reverse micelle method and synthesizing the leptin modified targeted hair papilla cell lipidosome by adopting a film hydration method. The lipidosome is of a spherical lipid double-layer nano structure with an outer layer lipid and a water-based core, the structure of the lipidosome allows the lipidosome to load hydrophilic drugs in the core and load hydrophobic drugs between the double layers, and phospholipid in the lipidosome can rearrange intercellular lipids, provide space for drug accumulation and enhance skin delivery, so that the lipidosome can be used for preventing and treating intercellular lipids. In addition, due to the lipophilicity of epithelial cells, the epithelial cells become an effective delivery system penetrating through hair follicles, the leptin can target hair papilla cells (DPC) through a leptin receptor (LEPR), the lipidosome is modified by the leptin, and the lipidosome is connected with the leptin to target the hair papilla cells, so that the androgenetic alopecia can be accurately treated.

Leptin receptor (LEPR) is a single-pass transmembrane receptor that belongs to the cytokine receptor family. The secreted ligand Leptin binds to LEPR and activates intracellular downstream signal cascades. Leptin and LEPR play critical role in body weight regulation. The antibodies of the present disclosure have agonistic activities on LEPR and can therefore be used as therapeutic agents to treat obesity.

To provide a material for regenerating a tissue which can obtain a marrow-derived mesenchymal stem cell having a given number or more of leptin receptor positive cells from a marrow tissue in a short time and by a simple treatment.SOLUTION: A material for regenerating tissue in which a marrow-derived mesenchymal stem cell is separated from a marrow tissue. The material for regenerating tissue includes a marrow-derived mesenchymal stem cell in which a leptin receptor positive cell number shows 5.0×104 or more.SELECTED DRAWING: None

Provided herein are therapeutic methods for treatment using an agonist leptin receptor (LEPR) antibody, an antigen-binding fragment thereof, or a composition comprising the LEPR antibody or an antigen-binding fragment thereof. Such methods of treatment include treating conditions associated with metabolic dysfunction, including, for example, lipodystrophy, obesity predisposition or obesity, weight loss, non-alcoholic fatty liver disease, overappetite, hyperglycemia, insulin resistance, dyslipidemia, hepatic steatosis, and infertility.

The invention relates to a polypeptide comprising a variant of a protein of the Sac7d family that specifically binds to the human leptin receptor and is able to trigger the crossing of the intestinal barrier, in particular of biologicals associated with it.

The present invention provides a combination of antagonists of leptin receptor, GDF8 and activin A and methods of using the same. The composition is effective, for example, to increase lean body mass at least in part at the expense of fat mass. Methods of treating malnutrition, cachexia and other conditions characterized by nutritional deficiencies and weight loss are also provided.

Provided herein are therapeutic methods of treatment using an agonist leptin receptor (LEPR) antibody, antigen-binding fragment thereof, or a composition comprising the LEPR antibody or antigen-binding fragment thereof, to perform the treatment. Such therapeutic methods include treating conditions associated with metabolic dysfunction, including, for example, lipodystrophy, obesity predisposition or obesity, weight loss, nonalcoholic fatty liver disease, bulimia, hyperglycemia, insulin resistance, dyslipidemia, hepatic steatosis, and infertility.

This invention belongs to the field of experimental animal model construction technology, specifically relating to the construction method and application of a recombinant inbred type 2 diabetic rat model. The parent rats are SD (fa+ / +) or Wistar (fa+ / +) females and Zucker (fa+ / -) males. Heterozygous (fa+ / -) female offspring are backcrossed with the fathers until the F6 generation. Then, F6 heterozygous (fa+ / -) female rats are crossed with F6 heterozygous (fa+ / -) male rats. The resulting homozygous (fa- / -) SD / Zucker or Wistar / Zucker rats are the recombinant inbred type 2 diabetic rats. The rats obtained by this invention do not express functional leptin receptors, exhibit hyperphagia, and spontaneous polydipsia and polyphagia, which closely resembles the real-world scenario of type 2 diabetes caused by overnutrition under normal dietary conditions in humans.

The invention provides a marker for predicting the curative effect of anti-depression treatment. The marker is selected from one or more of plasma cytokines OPN, PF4, CD163, Syndecan-1, ACE-2, a leptin receptor (leptin R) and BMPR-1A (bone morphogenetic protein receptor-1A). The invention also provides an application of the plasma cell factor in preparation of a product for predicting the curative effect of the anti-depression treatment, and the plasma cell factor is selected from one or more of OPN, PF4, CD163, Syndecan-1, ACE-2, leptin R and BMPR-1A, and has relatively high MDD curative effect prediction efficiency.

One object of this disclosure is to provide a protein whose fluorescence increases when bound to leptin. [Solution] Starting from the N-terminus, (a) the N-terminal fragment of the fluorescent protein, (b) the first linker, (c) the C-terminal fragment of the leptin-binding domain derived from the leptin receptor, (d) the synthetic linker, The present invention provides a protein comprising (e) the N-terminal fragment of a leptin-binding domain derived from a leptin receptor, (f) a second linker, and (g) the amino acid sequence of the C-terminal fragment of a fluorescent protein, wherein when the C-terminal fragment of the leptin-binding domain derived from a leptin receptor and the N-terminal fragment of the leptin-binding domain derived from a leptin receptor bind to leptin, the fluorescence emitted from the N-terminal fragment of the fluorescent protein and the C-terminal fragment of the fluorescent protein increases.